Literature DB >> 26392546

Assessing sequence plasticity of a virus-like nanoparticle by evolution toward a versatile scaffold for vaccines and drug delivery.

Yuan Lu1, Wei Chan1, Benjamin Y Ko1, Christopher C VanLang1, James R Swartz2.   

Abstract

Virus-like particles (VLPs) have been extensively explored as nanoparticle vehicles for many applications in biotechnology (e.g., vaccines, drug delivery, imaging agents, biocatalysts). However, amino acid sequence plasticity relative to subunit expression and nanoparticle assembly has not been explored. Whereas the hepatitis B core protein (HBc) VLP appears to be the most promising model for fundamental and applied studies; particle instability, antigen fusion limitations, and intrinsic immunogenicity have limited its development. Here, we apply Escherichia coli-based cell-free protein synthesis (CFPS) to rapidly produce and screen HBc protein variants that still self-assemble into VLPs. To improve nanoparticle stability, artificial covalent disulfide bridges were introduced throughout the VLP. Negative charges on the HBc VLP surface were then reduced to improve surface conjugation. However, removal of surface negative charges caused low subunit solubility and poor VLP assembly. Solubility and assembly as well as surface conjugation were greatly improved by transplanting a rare spike region onto the common shell structure. The newly stabilized and extensively modified HBc VLP had almost no immunogenicity in mice, demonstrating great promise for medical applications. This study introduces a general paradigm for functional improvement of complex protein assemblies such as VLPs. This is the first study, to our knowledge, to systematically explore the sequence plasticity of viral capsids as an approach to defining structure function relationships for viral capsid proteins. Our observations on the unexpected importance of the HBc spike tip charged state may also suggest new mechanistic routes toward viral therapeutics that block capsid assembly.

Entities:  

Keywords:  cell-free protein synthesis; disulfide stabilization; engineered nanoparticles; hepatitis core protein; virus-like particle

Mesh:

Substances:

Year:  2015        PMID: 26392546      PMCID: PMC4603490          DOI: 10.1073/pnas.1510533112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

Review 1.  Hepatitis B virus infection--natural history and clinical consequences.

Authors:  Don Ganem; Alfred M Prince
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

2.  Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistry.

Authors:  Kedar G Patel; James R Swartz
Journal:  Bioconjug Chem       Date:  2011-02-28       Impact factor: 4.774

Review 3.  Keyhole limpet hemocyanin (KLH): a biomedical review.

Authors:  J R Harris; J Markl
Journal:  Micron       Date:  1999-12       Impact factor: 2.251

4.  HBV core region variability: effect of antiviral treatments on main epitopic regions.

Authors:  Maria Homs; Rosendo Jardi; Maria Buti; Melanie Schaper; David Tabernero; Pilar Fernandez-Fernandez; Josep Quer; Rafael Esteban; Francisco Rodriguez-Frias
Journal:  Antivir Ther       Date:  2011

Review 5.  HBV core particles as a carrier for B cell/T cell epitopes.

Authors:  P Pumpens; E Grens
Journal:  Intervirology       Date:  2001       Impact factor: 1.763

6.  Versatile virus-like particle carrier for epitope based vaccines.

Authors:  Alain C Tissot; Regina Renhofa; Nicole Schmitz; Indulis Cielens; Edwin Meijerink; Velta Ose; Gary T Jennings; Philippe Saudan; Paul Pumpens; Martin F Bachmann
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

7.  Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice.

Authors:  Iraklis C Kourtis; Sachiko Hirosue; Alexandre de Titta; Stephan Kontos; Toon Stegmann; Jeffrey A Hubbell; Melody A Swartz
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

8.  Microscale to manufacturing scale-up of cell-free cytokine production--a new approach for shortening protein production development timelines.

Authors:  James F Zawada; Gang Yin; Alexander R Steiner; Junhao Yang; Alpana Naresh; Sushmita M Roy; Daniel S Gold; Henry G Heinsohn; Christopher J Murray
Journal:  Biotechnol Bioeng       Date:  2011-03-31       Impact factor: 4.530

9.  The Pfam protein families database.

Authors:  Marco Punta; Penny C Coggill; Ruth Y Eberhardt; Jaina Mistry; John Tate; Chris Boursnell; Ningze Pang; Kristoffer Forslund; Goran Ceric; Jody Clements; Andreas Heger; Liisa Holm; Erik L L Sonnhammer; Sean R Eddy; Alex Bateman; Robert D Finn
Journal:  Nucleic Acids Res       Date:  2011-11-29       Impact factor: 16.971

Review 10.  Construction and characterization of virus-like particles: a review.

Authors:  Andris Zeltins
Journal:  Mol Biotechnol       Date:  2013-01       Impact factor: 2.695

View more
  33 in total

Review 1.  Nanoparticle systems for cancer vaccine.

Authors:  Ru Wen; Afoma C Umeano; Yi Kou; Jian Xu; Ammad Ahmad Farooqi
Journal:  Nanomedicine (Lond)       Date:  2019-02-26       Impact factor: 5.307

2.  Evaluation of lumazine synthase from Bacillus anthracis as a presentation platform for polyvalent antigen display.

Authors:  Yangjie Wei; Newton Wahome; Greta VanSlyke; Neal Whitaker; Prashant Kumar; Michael L Barta; Wendy L Picking; David B Volkin; Nicholas J Mantis; C Russell Middaugh
Journal:  Protein Sci       Date:  2017-09-13       Impact factor: 6.725

Review 3.  The growing impact of lyophilized cell-free protein expression systems.

Authors:  J Porter Hunt; Seung Ook Yang; Kristen M Wilding; Bradley C Bundy
Journal:  Bioengineered       Date:  2016-10-28       Impact factor: 3.269

Review 4.  Cell-Free Synthetic Biology: Engineering Beyond the Cell.

Authors:  Jessica G Perez; Jessica C Stark; Michael C Jewett
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-12-01       Impact factor: 10.005

Review 5.  Strategies for Browning Agent Delivery.

Authors:  Wentao Zhang; Tao Sheng; Zhen Gu; Yuqi Zhang
Journal:  Pharm Res       Date:  2021-08-16       Impact factor: 4.200

Review 6.  Engineering virus-like particles as vaccine platforms.

Authors:  Kathryn M Frietze; David S Peabody; Bryce Chackerian
Journal:  Curr Opin Virol       Date:  2016-03-29       Impact factor: 7.090

7.  A bivalent antihypertensive vaccine targeting L-type calcium channels and angiotensin AT1 receptors.

Authors:  Hailang Wu; Yiyi Wang; Gongxin Wang; Zhihua Qiu; Xiajun Hu; Hongrong Zhang; Xiaole Yan; Fan Ke; Anruo Zou; Min Wang; Yuhua Liao; Xiao Chen
Journal:  Br J Pharmacol       Date:  2019-12-12       Impact factor: 8.739

8.  Disulfide Bridging Strategies in Viral and Nonviral Platforms for Nucleic Acid Delivery.

Authors:  Kingshuk Dutta; Ritam Das; Jewel Medeiros; S Thayumanavan
Journal:  Biochemistry       Date:  2021-01-11       Impact factor: 3.162

Review 9.  Protein-based antigen presentation platforms for nanoparticle vaccines.

Authors:  Brian Nguyen; Niraj H Tolia
Journal:  NPJ Vaccines       Date:  2021-05-13       Impact factor: 7.344

10.  Tubule-specific protein nanocages potentiate targeted renal fibrosis therapy.

Authors:  Xuan Zhang; Qian Chen; Liyuan Zhang; Haiping Zheng; Chunjie Lin; Qunfang Yang; Tao Liu; Haigang Zhang; Xiaohong Chen; Lei Ren; Wenjun Shan
Journal:  J Nanobiotechnology       Date:  2021-05-26       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.